The state of Missouri currently has 18 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Fluvoxamine for Long COVID-19
NCT05874037
Recruiting
This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois.
Gender:
All
Ages:
25 years and above
Trial Updated:
08/10/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Long COVID
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
All
Ages:
All
Trial Updated:
07/19/2023
Locations: Washington University, Saint Louis, Missouri
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
NCT05947643
Recruiting
The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be asked to rinse their nose with a medication or placebo capsule dissolved in saltwater twice daily for 12 weeks and fill out surveys about smell before, during, and at the end of treatment. This study... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/13/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: COVID-19
Register for Updates
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
NCT05280717
Recruiting
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy participants aged 18 to 65 years. The study will be conducted in three parts (Part A, an optional Part B and Part C).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/02/2022
Locations: Investigative Site, Saint Louis, Missouri
Conditions: Covid19
Register for Updates
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
NCT05387278
Recruiting
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmon... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/11/2022
Locations: Kit Bartalos, Liberty, Missouri
Conditions: COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Register for Updates
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
NCT05037097
Recruiting
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
11/10/2021
Locations: Arcturus Investigational Site 201, Kansas City, Missouri
Conditions: COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
Register for Updates